Twitter

Chordate CEO Anders Weilandt to give presentation at Life Science Day on March 8th

Chordate Medical is one of the companies participating at this years’ Life Science Day in Gothenburg on March 8th. Chordate CEO Anders Weilandt will present the company and how K.O.S can become a global and valuable treatment option for people with chronic migraines.

The Life Science day takes place at the Wallenberg conference center next to Sahlgrenska in Gothenburg and consists of presentations by 15 companies active in the Life Science and Medtech sector, as well as professors and researchers.

The event is live streamed and can be seen afterwards at https://www.lifesciencedagen.se/

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked a neuromodulation and drug-free treatment technology for chronic migraine and chronic nasal congestion (rhinitis), Kinetic Oscillation Stimulation (K.O.S). The K.O.S-treatment has clinically proven efficacy according to scientific studies. The company's products are available via distributors to clinics in the Nordic countries, Germany, the UK, Italy, Israel, and Saudi Arabia. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments
Chordate CEO Anders Weilandt to give presentation at Life Science Day on March 8th

Chordate CEO Anders Weilandt to give presentation at Life Science Day on March 8th

More press releases

Investor relations

Subscribe

Press releases and reports via E-mail.

Detta fält används för valideringsändamål och ska lämnas oförändrat.

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact

Anders Weilandt, CEO

+46(0)73-387 42 77 anders.weilandt@chordate.com

Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical’s share is listed on the Nasdaq First North Growth Market (ticker: CMH).

Press releases

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter